checkAd

Masimo Announces CE Marking of Neonatal Indication for Noninvasive, Continuous Hemoglobin Monitoring (SpHb)

Nachrichtenquelle: Business Wire (engl.)
05.08.2019, 08:00  |  216   |   |   

Masimo (NASDAQ: MASI) announced today the CE marking of SpHb, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients (< 3 kg). With this clearance, the benefits of SpHb are available for patients of all ages in CE mark countries. SpHb for neonates and infants is provided on rainbow sensors, which allow clinicians to simultaneously measure multiple additional noninvasive parameters alongside SpHb, including oxygen saturation (SpO2) and methemoglobin (SpMet).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190804005042/en/

Masimo Root with SpHb and PVi (Photo: Business Wire)

Masimo Root with SpHb and PVi (Photo: Business Wire)

Because of their small size, neonates and infants have less blood than older patients. In addition, their lack of bone marrow density makes them far less capable than adults of generating new red blood cells for approximately the first eight months of life. Current invasive methodologies for measuring hemoglobin can only provide intermittent, delayed results. By providing a continuous, noninvasive measurement, SpHb allows clinicians to more closely monitor neonatal hemoglobin status in real time by tracking the stability, or instability, of a patient’s hemoglobin trend, providing visibility into changes, or lack of changes, in hemoglobin between invasive blood samples.

On adult patients, continuous monitoring with SpHb has been found to improve outcomes, such as reducing the percentage of patients receiving transfusions,1 reducing the units of red blood cells transfused per patient,2-3 reducing the time to transfusion,4 reducing costs,5 and even reducing mortality 30 days after surgery.6

In addition to hemoglobin, rainbow sensors monitor SpO2 using Masimo SET Measure-through Motion and Low Perfusion technology, which has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.7 Crucially for newborn health, SET has been shown to help clinicians reduce severe retinopathy of prematurity in neonates8 and in multiple studies, including the largest critical congenital heart disease (CCHD) study to date, to improve CCHD screening in newborns.9-10

The rainbow family of advanced noninvasive measurements also allows clinicians to use the same single sensor to monitor another physiological parameter particularly important to neonatal care: methemoglobin, using SpMet. SpMet helps clinicians noninvasively and continuously monitor methemoglobin levels in the blood.11 In neonates and infants, inhaled nitric oxide (iNO) therapy and even topical anesthetics containing benzocaine or prilocaine can cause elevated levels of methemoglobin.12-13

Seite 1 von 4
Masimo Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Masimo Announces CE Marking of Neonatal Indication for Noninvasive, Continuous Hemoglobin Monitoring (SpHb) Masimo (NASDAQ: MASI) announced today the CE marking of SpHb, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients (< 3 kg). With this clearance, the benefits of SpHb are available for patients of all ages in CE mark …

Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

DatumTitel
15.09.21Masimo lanciert rainbow SuperSensor zur Verwendung bei einem Patienten
Business Wire (dt.) | Weitere Nachrichten
13.09.21Masimo Launches Single-patient-use rainbow SuperSensor
Business Wire (engl.) | Weitere Nachrichten
08.09.21Masimo to Present in Morgan Stanley 19th Annual Global Healthcare Conference
Business Wire (engl.) | Weitere Nachrichten
06.09.21Neue Studie erforscht die Eignung von Masimo ORi zur Frühwarnung vor Hypoxämie während der endotrachealen Intubation bei Intensivpatienten
Business Wire (dt.) | Weitere Nachrichten
06.09.21New Study Investigates the Ability of Masimo ORi to Provide Early Warning of Hypoxemia During Endotracheal Intubation in ICU Patients
Business Wire (engl.) | Weitere Nachrichten
01.09.21Masimo arbeitet zusammen mit dem Penington Institute an einer Aufklärungskampagne zu den Schäden infolge einer Überdosierung von verschreibungspflichtigen Opioiden
Business Wire (dt.) | Weitere Nachrichten
31.08.21SafetyNet Alert von Masimo kommt in Westeuropa auf den Markt
Business Wire (dt.) | Weitere Nachrichten
31.08.21Masimo Partners with Penington Institute to Raise Awareness of Harm from Prescription Opioid Overdose
Business Wire (engl.) | Weitere Nachrichten
30.08.21Masimo SafetyNet Alert Launches in Western Europe
Business Wire (engl.) | Weitere Nachrichten
28.08.21Die Veröffentlichung der Society for the Advancement of Patient Blood Management (SABM) empfiehlt eine kontinuierliche Hämoglobinüberwachung
Business Wire (dt.) | Weitere Nachrichten